BiVictriX Therapeutics Plc (BVX.L)

11.50 0.00 (0.00%) At close: 09:39AM BST

BiVictriX Therapeutics Plc

Alderley Park
Alderley Edge Cheshire
Macclesfield SK10 4TG
United Kingdom

https://www.bivictrix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Tiffany Jane Thorn BSc. MSc., M.Sc.	CEO & Executive Director	192.5k	N/A	1987
Dr. Adrian Howd Ph.D.	Chief Business Officer & CFO	N/A	N/A	1971
Simon Wallwork	Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

Corporate governance

BiVictriX Therapeutics Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.